Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes

6 Jul 2015

Abstract excerpt

Hepatitis C virus (HCV) entry inhibitors (EIs) act synergistically with drugs targeting other stages of the HCV lifecycle. The origin of this synergy remains unknown. Here, we argue that the synergy may arise from the complementary activities of the drugs across cell subpopulations expressing different levels of HCV entry receptors. We employ mathematical modeling of viral kinetics in vitro, where cells with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to Liver Disease Diagnosis and Treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26380153
DOI: 10.1002/psp4.12005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesPMID 26380153Read ↗

Building a mechanistic mathematical model of hepatitis C virus entrySemantic proximity Read ↗

Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Semantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus EntrySemantic proximity Read ↗

Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.Semantic proximity Read ↗

Identification of novel antiviral drug combinations in vitro and tracking their developmentSemantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infectionSemantic proximity Read ↗

Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2Semantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infection.Semantic proximity Read ↗

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral AgentsSemantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infectionSemantic proximity Read ↗

A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.